EF Hutton analyst Jason Kolbert maintains Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $6 price target.
EF Hutton Maintains Buy on Citius Pharma, Maintains $6 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.